We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven ...

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- (ANI or the Company) (Nasdaq: ANIP) today announced that following final ...

The global panuveitis treatment market achieved a significant value of USD 3.76 billion in 2022 and is projected to reach ...

These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera ...

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

With ophthalmology assets Iluvien and Yutiq added from the company's recent acquisition of Alimera Sciences, ANI's (ANIP) rare disease portfolio should make up more than 45% of the company's ...